Artegraft, Inc. was incorporated in January, 1993, upon the divestiture of the bovine vascular graft business from Johnson & Johnson.Artegraft was the first vascular graft approved by the FDA (1970) and has been in continuous clinical use for over 40 years.

Available in lengths from 15 to 50cm and in 6, 7 and 8mm diameters, Artegraft is approved for use, distal to the aorta, for segmental bypass, arterial replacement, patch graft, femoropopliteal bypass when the patient's saphenous is absent or inadequate, but is predominantly used as a hemodialysis graft. Artegraft is a Class III, life-sustaining implantable medical device.